Details of the Drug
General Information of Drug (ID: DMR1HQ3)
Drug Name |
(S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
58521-45-2; TERT-BUTYL (S)1-FORMYL-3-METHYLBUTYLCARBAMATE; Boc-Leucinal; N-t-butoxycarbonyl-L-leucinal; CHEMBL96823; N-Boc-2(S)-2-amino-4-methyl-pentanal; tert-butyl N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate; Boc-Leu-H; Boc--L--Leucinal; (S)-Boc-Leucinal; t-Boc-Leu-H; BOC-L-LEUCINAL; BOC-LEU-CHO; AC1L2WGL; N--BOC--L--leucinal; t-butoxycarbonyl-L-leucinal; tert-butyl (1S)-1-formyl-3-methylbutylcarbamate; tert-butyloxycarbonyl-leucinal; SCHEMBL739719; N-tert-butoxycarbonyl-L-leucinal; (t-Butyloxycarbonyl)-L-Leucinal
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 215.29 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||